Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 615

1.

Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.

Brunet S, Esteve J, Berlanga J, Ribera JM, Bueno J, Martí JM, Bargay J, Guardia R, Juliá A, Granena A, Montserrat E, Sierra J; Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias.

Haematologica. 2004 Aug;89(8):940-9.

2.

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia.

Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, Skandali A, Sakellari I, Yataganas X; Hellenic Cooperative Group.

Cancer. 2003 Apr 1;97(7):1721-31.

3.

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.

Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.

Ann Hematol. 2003 Nov;82(11):684-90. Epub 2003 Aug 19.

PMID:
12928754
4.

Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.

Thomas X, Suciu S, Rio B, Leone G, Broccia G, Fillet G, Jehn U, Feremans W, Meloni G, Vignetti M, de Witte T, Amadori S.

Haematologica. 2007 Mar;92(3):389-96.

5.

Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.

Thomas X, Le Q, Botton Sd, Raffoux E, Chelghoum Y, Pautas C, Dreyfus F, Dhedin N, Vekhoff A, Troncy J, Pigneux A, Revel Td, Reman O, Travade P, Thiebaut A, Guerci A, Elhamri M, Fenaux P, Dombret H, Michallet M.

Leuk Lymphoma. 2005 Jul;46(7):1007-16.

PMID:
16019551
6.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
7.

Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.

Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M.

Eur J Haematol. 2009 Aug;83(2):99-107. doi: 10.1111/j.1600-0609.2009.01256.x. Epub 2009 Apr 6.

PMID:
19385987
8.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R; EORTC and GIMEMA Leukemia Groups.

Blood. 2003 Aug 15;102(4):1232-40. Epub 2003 Apr 24.

9.

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R.

Blood. 2001 Oct 15;98(8):2326-31. Erratum in: Blood 2002 Mar 1;99(5):1535.

10.

Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.

Visani G, Lemoli RM, Isidori A, Piccaluga PP, Martinelli G, Malagola M, Gugliotta L, Bonini A, Bonifazi F, Motta MR, Rizzi S, Castellani S, Tura S.

Bone Marrow Transplant. 2001 Apr;27(8):829-35.

11.

Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.

Shin HJ, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH; Korean Society of Hematology, AML/MDS Working Party, Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM.

Jpn J Clin Oncol. 2010 Jun;40(6):556-66. doi: 10.1093/jjco/hyq007. Epub 2010 Feb 25.

PMID:
20185460
12.

The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.

Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S.

Leukemia. 2001 Jun;15(6):903-9. Review.

PMID:
11417475
13.

Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients.

Russo D, Malagola M, de Vivo A, Fiacchini M, Martinelli G, Piccaluga PP, Damiani D, Candoni A, Michielutti A, Castelli M, Testoni N, Ottaviani E, Rondoni M, Pricolo G, Mazza P, Zuffa E, Zaccaria A, Raspadori D, Bocchia M, Lauria F, Bonini A, Avanzini P, Gugliotta L, Visani G, Fanin R, Baccarani M.

Br J Haematol. 2005 Oct;131(2):172-9. Erratum in: Br J Haematol. 2006 Mar;132(6):804.

PMID:
16197446
14.

Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment.

Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ, Perreau V, Coso D, Pigneux A, Vey N.

Cancer. 2005 Nov 1;104(9):1931-8.

15.

Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.

Ribera JM, Oriol A, Bethencourt C, Parody R, Hernández-Rivas JM, Moreno MJ, del Potro E, Torm M, Rivas C, Besalduch J, Sanz MA, Ortega JJ; PETHEMA Group, Spain.

Haematologica. 2005 Oct;90(10):1346-56.

16.

Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.

Wahlin A, Brinch L, Hörnsten P, Evensen SA, Oberg G, Simonsson B, Hedenus M.

Eur J Haematol. 1997 Apr;58(4):233-40.

PMID:
9186533
17.

Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.

Oriol A, Ribera JM, Esteve J, Guàrdia R, Brunet S, Bueno J, Pedro C, Llorente A, Tormo M, Besalduch J, Sánchez JM, Batlle M, Vivancos P, Carreras E, Vilà JM, Julià A, Sierra J, Montserrat E, Feliu E; CETLAM AML-99.

Haematologica. 2004 Jul;89(7):791-800.

18.

Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.

Bassan R, Raimondi R, Lerede T, D'emilio A, Buelli M, Borleri G, Personeni A, Bellavita P, Rodeghiero F, Barbui T.

Haematologica. 1998 Jul;83(7):627-35.

20.

Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.

Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group.

Pediatr Blood Cancer. 2007 Aug;49(2):127-32.

PMID:
16807916

Supplemental Content

Support Center